KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $54.1 million.

  • Amneal Pharmaceuticals' Depreciation & Amortization (CF) fell 829.02% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 593.89%. This contributed to the annual value of $236.2 million for FY2024, which is 296.03% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $54.1 million for Q3 2025, which was down 829.02% from $60.1 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $66.1 million for Q4 2024, and its period low was $54.1 million during Q3 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' median Depreciation & Amortization (CF) value was $58.2 million (recorded in 2023), while the average stood at $58.6 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 1615.41% in 2024, then tumbled by 829.02% in 2025.
  • Amneal Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $61.2 million in 2021, then fell by 0.21% to $61.1 million in 2022, then fell by 6.75% to $56.9 million in 2023, then increased by 16.15% to $66.1 million in 2024, then dropped by 18.23% to $54.1 million in 2025.
  • Its Depreciation & Amortization (CF) was $54.1 million in Q3 2025, compared to $60.1 million in Q2 2025 and $60.2 million in Q1 2025.